| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 39 | 2023 | 158 | 7.600 |
Why?
|
| Lupus Erythematosus, Systemic | 22 | 2024 | 35 | 3.940 |
Why?
|
| Scleroderma, Systemic | 20 | 2021 | 43 | 3.180 |
Why?
|
| Antirheumatic Agents | 13 | 2021 | 35 | 2.410 |
Why?
|
| Autoantibodies | 19 | 2023 | 49 | 2.400 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2022 | 176 | 2.310 |
Why?
|
| Severity of Illness Index | 21 | 2024 | 253 | 2.170 |
Why?
|
| Rheumatic Diseases | 7 | 2021 | 17 | 2.150 |
Why?
|
| Humans | 118 | 2024 | 14537 | 2.130 |
Why?
|
| Quality of Life | 11 | 2024 | 177 | 2.070 |
Why?
|
| Rheumatoid Factor | 6 | 2019 | 16 | 2.050 |
Why?
|
| Middle Aged | 61 | 2024 | 3601 | 2.030 |
Why?
|
| Female | 83 | 2024 | 9103 | 1.940 |
Why?
|
| Male | 68 | 2024 | 6754 | 1.830 |
Why?
|
| Psoriasis | 3 | 2019 | 10 | 1.730 |
Why?
|
| Adult | 66 | 2024 | 5913 | 1.710 |
Why?
|
| Disability Evaluation | 8 | 2024 | 22 | 1.710 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 3 | 2018 | 7 | 1.680 |
Why?
|
| Metabolic Syndrome | 3 | 2019 | 64 | 1.640 |
Why?
|
| Rheumatology | 6 | 2021 | 18 | 1.580 |
Why?
|
| South Africa | 48 | 2024 | 7596 | 1.390 |
Why?
|
| Activities of Daily Living | 5 | 2024 | 41 | 1.220 |
Why?
|
| Cost of Illness | 3 | 2024 | 167 | 1.160 |
Why?
|
| Case-Control Studies | 15 | 2019 | 480 | 1.070 |
Why?
|
| Aged | 29 | 2021 | 1740 | 1.020 |
Why?
|
| Antibodies, Antinuclear | 9 | 2020 | 13 | 0.970 |
Why?
|
| Risk Factors | 22 | 2024 | 1475 | 0.950 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 237 | 0.920 |
Why?
|
| Botulinum Toxins | 2 | 2022 | 2 | 0.900 |
Why?
|
| Esotropia | 2 | 2022 | 2 | 0.900 |
Why?
|
| Polymorphism, Genetic | 7 | 2009 | 99 | 0.890 |
Why?
|
| Peptides, Cyclic | 4 | 2023 | 8 | 0.820 |
Why?
|
| Developing Countries | 6 | 2018 | 400 | 0.810 |
Why?
|
| Retrospective Studies | 14 | 2019 | 799 | 0.760 |
Why?
|
| Smoking | 5 | 2018 | 100 | 0.750 |
Why?
|
| Scleroderma, Diffuse | 3 | 2018 | 7 | 0.740 |
Why?
|
| Skin | 4 | 2018 | 38 | 0.730 |
Why?
|
| HLA-DRB1 Chains | 4 | 2022 | 17 | 0.710 |
Why?
|
| Prevalence | 13 | 2020 | 1192 | 0.700 |
Why?
|
| Treatment Outcome | 13 | 2022 | 889 | 0.660 |
Why?
|
| Cytokines | 4 | 2015 | 107 | 0.630 |
Why?
|
| Takayasu Arteritis | 1 | 2019 | 6 | 0.620 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2019 | 9 | 0.620 |
Why?
|
| Intra-Abdominal Fat | 1 | 2019 | 15 | 0.620 |
Why?
|
| Adipokines | 1 | 2019 | 11 | 0.620 |
Why?
|
| Cross-Sectional Studies | 12 | 2019 | 1422 | 0.610 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2019 | 1 | 0.600 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2019 | 1 | 0.600 |
Why?
|
| African Americans | 2 | 2018 | 47 | 0.590 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 1 | 0.570 |
Why?
|
| Amino Acids | 1 | 2018 | 16 | 0.570 |
Why?
|
| Methotrexate | 4 | 2019 | 17 | 0.570 |
Why?
|
| Immunoglobulin A | 2 | 2018 | 39 | 0.570 |
Why?
|
| Tobacco Use | 1 | 2018 | 12 | 0.560 |
Why?
|
| Prognosis | 8 | 2019 | 199 | 0.550 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 563 | 0.540 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 231 | 0.540 |
Why?
|
| Biomarkers | 10 | 2019 | 327 | 0.520 |
Why?
|
| Arthritis, Infectious | 2 | 2009 | 7 | 0.520 |
Why?
|
| Prednisone | 2 | 2019 | 17 | 0.510 |
Why?
|
| Lung | 2 | 2020 | 70 | 0.500 |
Why?
|
| Health Status | 6 | 2016 | 111 | 0.480 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2014 | 4 | 0.480 |
Why?
|
| Citrulline | 1 | 2016 | 2 | 0.480 |
Why?
|
| Air Pollution | 1 | 2016 | 2 | 0.480 |
Why?
|
| Biological Products | 2 | 2021 | 7 | 0.460 |
Why?
|
| Vasculitis | 2 | 2014 | 4 | 0.440 |
Why?
|
| Disease Progression | 6 | 2019 | 154 | 0.440 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 44 | 0.440 |
Why?
|
| Genotype | 8 | 2018 | 442 | 0.430 |
Why?
|
| Spondylarthritis | 1 | 2014 | 2 | 0.430 |
Why?
|
| Biological Factors | 1 | 2014 | 1 | 0.420 |
Why?
|
| Biological Therapy | 1 | 2014 | 1 | 0.420 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2014 | 7 | 0.420 |
Why?
|
| Dermatomyositis | 1 | 2014 | 2 | 0.410 |
Why?
|
| Opportunistic Infections | 3 | 2014 | 10 | 0.410 |
Why?
|
| Calcinosis | 1 | 2014 | 11 | 0.410 |
Why?
|
| Prospective Studies | 8 | 2022 | 1160 | 0.410 |
Why?
|
| C-Reactive Protein | 5 | 2019 | 96 | 0.400 |
Why?
|
| Tuberculosis | 3 | 2019 | 543 | 0.400 |
Why?
|
| Sulfasalazine | 2 | 2011 | 4 | 0.400 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 31 | 0.400 |
Why?
|
| Time Factors | 9 | 2019 | 507 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2022 | 198 | 0.400 |
Why?
|
| Africa | 4 | 2021 | 376 | 0.390 |
Why?
|
| Pregnancy Outcome | 3 | 2019 | 117 | 0.390 |
Why?
|
| Rheumatoid Nodule | 1 | 2012 | 2 | 0.380 |
Why?
|
| Th1 Cells | 1 | 2012 | 6 | 0.370 |
Why?
|
| HIV Infections | 5 | 2014 | 5097 | 0.370 |
Why?
|
| Young Adult | 8 | 2020 | 2498 | 0.370 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2012 | 2 | 0.360 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2012 | 4 | 0.360 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 4 | 0.360 |
Why?
|
| Skin Physiological Phenomena | 1 | 2012 | 5 | 0.360 |
Why?
|
| Chloroquine | 1 | 2011 | 10 | 0.360 |
Why?
|
| HIV | 1 | 2014 | 380 | 0.350 |
Why?
|
| Bone Density | 4 | 2016 | 107 | 0.350 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 188 | 0.350 |
Why?
|
| Comorbidity | 4 | 2021 | 188 | 0.350 |
Why?
|
| Antibody Specificity | 1 | 2011 | 30 | 0.340 |
Why?
|
| Antibodies | 1 | 2011 | 25 | 0.340 |
Why?
|
| Mastitis | 1 | 2011 | 1 | 0.340 |
Why?
|
| Rheumatologists | 2 | 2021 | 2 | 0.340 |
Why?
|
| Incidence | 6 | 2021 | 685 | 0.340 |
Why?
|
| Age of Onset | 4 | 2019 | 32 | 0.330 |
Why?
|
| Risk Assessment | 3 | 2019 | 225 | 0.330 |
Why?
|
| Longitudinal Studies | 6 | 2022 | 435 | 0.310 |
Why?
|
| Motor Activity | 3 | 2015 | 46 | 0.310 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 34 | 0.310 |
Why?
|
| Acute-Phase Proteins | 4 | 2018 | 14 | 0.310 |
Why?
|
| Mutation | 2 | 2018 | 306 | 0.300 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 370 | 0.300 |
Why?
|
| Lung Diseases | 4 | 2018 | 29 | 0.300 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2009 | 2 | 0.300 |
Why?
|
| Adolescent | 10 | 2020 | 2985 | 0.290 |
Why?
|
| Social Behavior | 1 | 2008 | 5 | 0.280 |
Why?
|
| Cohort Studies | 5 | 2018 | 967 | 0.280 |
Why?
|
| Early Diagnosis | 3 | 2014 | 82 | 0.280 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 171 | 0.280 |
Why?
|
| Databases, Factual | 7 | 2019 | 64 | 0.280 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2018 | 7 | 0.280 |
Why?
|
| Radiography | 9 | 2014 | 80 | 0.280 |
Why?
|
| Global Health | 1 | 2009 | 193 | 0.270 |
Why?
|
| Accelerometry | 4 | 2018 | 19 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2018 | 2 | 0.260 |
Why?
|
| Osteoarthritis, Knee | 2 | 2018 | 2 | 0.260 |
Why?
|
| Nucleosomes | 1 | 2007 | 1 | 0.260 |
Why?
|
| Drug Therapy, Combination | 5 | 2015 | 279 | 0.260 |
Why?
|
| Cardiac Tamponade | 1 | 2007 | 3 | 0.260 |
Why?
|
| Pericarditis, Tuberculous | 1 | 2007 | 8 | 0.260 |
Why?
|
| Pregnancy | 3 | 2019 | 1862 | 0.240 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2007 | 100 | 0.240 |
Why?
|
| Alleles | 5 | 2018 | 143 | 0.240 |
Why?
|
| Trace Elements | 1 | 2005 | 3 | 0.230 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 7 | 0.230 |
Why?
|
| Sex Factors | 5 | 2019 | 227 | 0.230 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 40 | 0.230 |
Why?
|
| NADPH Oxidases | 1 | 2005 | 1 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 43 | 0.230 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 4 | 0.230 |
Why?
|
| Phosphoproteins | 1 | 2005 | 10 | 0.230 |
Why?
|
| Vibration | 2 | 2016 | 7 | 0.230 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 195 | 0.230 |
Why?
|
| Neurotoxins | 2 | 2022 | 2 | 0.230 |
Why?
|
| Ophthalmologic Surgical Procedures | 2 | 2022 | 2 | 0.230 |
Why?
|
| Vision, Binocular | 2 | 2022 | 2 | 0.230 |
Why?
|
| Tricuspid Valve | 1 | 2005 | 1 | 0.220 |
Why?
|
| Phenotype | 3 | 2018 | 158 | 0.220 |
Why?
|
| Endocarditis | 1 | 2005 | 4 | 0.220 |
Why?
|
| Exercise | 2 | 2018 | 205 | 0.220 |
Why?
|
| Blood Sedimentation | 3 | 2014 | 12 | 0.220 |
Why?
|
| Delayed Diagnosis | 1 | 2024 | 17 | 0.220 |
Why?
|
| Free Radical Scavengers | 1 | 2004 | 6 | 0.210 |
Why?
|
| Superoxide Dismutase | 1 | 2004 | 6 | 0.210 |
Why?
|
| Oxygen | 1 | 2004 | 25 | 0.210 |
Why?
|
| HLA-D Antigens | 1 | 2004 | 2 | 0.210 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 20 | 0.210 |
Why?
|
| Streptococcus pneumoniae | 1 | 2007 | 336 | 0.210 |
Why?
|
| Pulmonary Fibrosis | 3 | 2004 | 9 | 0.210 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2004 | 1 | 0.210 |
Why?
|
| Logistic Models | 3 | 2019 | 254 | 0.210 |
Why?
|
| Drug Resistance | 2 | 2014 | 35 | 0.210 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 43 | 0.200 |
Why?
|
| HLA-B27 Antigen | 2 | 2014 | 2 | 0.200 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 8 | 0.200 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2007 | 329 | 0.200 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 385 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 468 | 0.200 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 1 | 0.200 |
Why?
|
| Hyperhomocysteinemia | 1 | 2003 | 2 | 0.200 |
Why?
|
| Echocardiography, Doppler | 2 | 2017 | 18 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 217 | 0.190 |
Why?
|
| Health Status Disparities | 2 | 2024 | 35 | 0.190 |
Why?
|
| Raynaud Disease | 3 | 2018 | 5 | 0.190 |
Why?
|
| Cervical Vertebrae | 1 | 2002 | 1 | 0.190 |
Why?
|
| Osteolysis | 1 | 2002 | 1 | 0.190 |
Why?
|
| Mandible | 1 | 2002 | 6 | 0.190 |
Why?
|
| Pain | 4 | 2019 | 41 | 0.190 |
Why?
|
| HLA Antigens | 1 | 2022 | 50 | 0.180 |
Why?
|
| Oculomotor Muscles | 1 | 2022 | 1 | 0.180 |
Why?
|
| Fatigue | 3 | 2019 | 20 | 0.180 |
Why?
|
| Myositis | 2 | 2018 | 4 | 0.180 |
Why?
|
| Regression Analysis | 3 | 2016 | 133 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 61 | 0.180 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 106 | 0.180 |
Why?
|
| Age Factors | 2 | 2019 | 370 | 0.170 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 299 | 0.170 |
Why?
|
| Registries | 2 | 2021 | 91 | 0.170 |
Why?
|
| Africa South of the Sahara | 3 | 2021 | 353 | 0.170 |
Why?
|
| Publications | 1 | 2021 | 2 | 0.170 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 20 | 0.170 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 63 | 0.170 |
Why?
|
| Child | 6 | 2021 | 2242 | 0.160 |
Why?
|
| Child, Preschool | 2 | 2022 | 1748 | 0.160 |
Why?
|
| Echocardiography | 2 | 2017 | 100 | 0.160 |
Why?
|
| Haplotypes | 2 | 2018 | 125 | 0.160 |
Why?
|
| Azathioprine | 1 | 2019 | 4 | 0.160 |
Why?
|
| Femoral Artery | 1 | 2019 | 11 | 0.160 |
Why?
|
| Skin Diseases | 2 | 2016 | 6 | 0.160 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2019 | 24 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2019 | 20 | 0.150 |
Why?
|
| Analysis of Variance | 1 | 2019 | 64 | 0.150 |
Why?
|
| Arthritis | 2 | 2014 | 8 | 0.150 |
Why?
|
| Sexuality | 1 | 2019 | 11 | 0.150 |
Why?
|
| Infant | 3 | 2022 | 2244 | 0.150 |
Why?
|
| Infertility | 1 | 2019 | 8 | 0.150 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 37 | 0.150 |
Why?
|
| Kidney Diseases | 2 | 2016 | 38 | 0.150 |
Why?
|
| Nail Diseases | 1 | 2019 | 1 | 0.150 |
Why?
|
| Aorta | 1 | 2019 | 43 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 10 | 0.150 |
Why?
|
| Endocarditis, Bacterial | 2 | 1997 | 7 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2019 | 79 | 0.150 |
Why?
|
| Poverty | 2 | 2011 | 152 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 26 | 0.150 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 55 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 27 | 0.150 |
Why?
|
| Gold | 1 | 1999 | 38 | 0.150 |
Why?
|
| Mining | 1 | 1999 | 41 | 0.140 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 7 | 0.140 |
Why?
|
| Scleroderma, Limited | 1 | 2018 | 1 | 0.140 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 11 | 0.140 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2018 | 1 | 0.140 |
Why?
|
| Frizzled Receptors | 1 | 2018 | 1 | 0.140 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2018 | 1 | 0.140 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2018 | 1 | 0.140 |
Why?
|
| SOXF Transcription Factors | 1 | 2018 | 1 | 0.140 |
Why?
|
| Axin Protein | 1 | 2018 | 1 | 0.140 |
Why?
|
| Wnt Proteins | 1 | 2018 | 2 | 0.140 |
Why?
|
| Heart Failure | 1 | 2019 | 38 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 5 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 9 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 7 | 0.140 |
Why?
|
| Transcriptome | 1 | 2018 | 14 | 0.140 |
Why?
|
| Heart Diseases | 2 | 2016 | 19 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2018 | 32 | 0.140 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2018 | 1 | 0.140 |
Why?
|
| Recovery of Function | 2 | 2016 | 11 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 77 | 0.140 |
Why?
|
| Disease Management | 2 | 2021 | 74 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 1 | 2018 | 21 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 37 | 0.140 |
Why?
|
| Gout | 1 | 1998 | 1 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 239 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 1998 | 23 | 0.140 |
Why?
|
| Urban Population | 2 | 1998 | 257 | 0.130 |
Why?
|
| Social Class | 1 | 2018 | 73 | 0.130 |
Why?
|
| Hypertension | 2 | 2019 | 419 | 0.130 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 4 | 0.130 |
Why?
|
| Systole | 1 | 2017 | 37 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 150 | 0.130 |
Why?
|
| Neisseria gonorrhoeae | 1 | 1997 | 15 | 0.130 |
Why?
|
| Gonorrhea | 1 | 1997 | 20 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 293 | 0.130 |
Why?
|
| Private Sector | 2 | 2014 | 45 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 8 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 280 | 0.120 |
Why?
|
| Cotinine | 1 | 2016 | 7 | 0.120 |
Why?
|
| Health Surveys | 2 | 2016 | 59 | 0.120 |
Why?
|
| Antitubercular Agents | 2 | 2011 | 322 | 0.120 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 7 | 0.120 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2016 | 1 | 0.120 |
Why?
|
| Hydrolases | 1 | 2016 | 1 | 0.120 |
Why?
|
| Cysts | 1 | 1996 | 2 | 0.120 |
Why?
|
| Ribonucleoproteins | 1 | 1996 | 6 | 0.120 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1996 | 9 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 10 | 0.120 |
Why?
|
| Autoantigens | 1 | 1996 | 10 | 0.120 |
Why?
|
| Models, Biological | 1 | 2016 | 77 | 0.120 |
Why?
|
| Skin Ulcer | 1 | 2015 | 3 | 0.120 |
Why?
|
| HLA-DR Antigens | 4 | 2004 | 13 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2015 | 321 | 0.110 |
Why?
|
| Disease Susceptibility | 4 | 2011 | 46 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 22 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2014 | 14 | 0.110 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2014 | 4 | 0.110 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2014 | 4 | 0.110 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2014 | 4 | 0.110 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2014 | 8 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2005 | 21 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 20 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 14 | 0.110 |
Why?
|
| Arthritis, Psoriatic | 1 | 2014 | 2 | 0.110 |
Why?
|
| Arthritis, Reactive | 1 | 2014 | 2 | 0.110 |
Why?
|
| Health Facility Closure | 1 | 2014 | 5 | 0.110 |
Why?
|
| Hospital Units | 1 | 2014 | 7 | 0.110 |
Why?
|
| Contracture | 1 | 2014 | 1 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2014 | 1 | 0.100 |
Why?
|
| Creatine Kinase, MM Form | 1 | 2014 | 1 | 0.100 |
Why?
|
| Exanthema | 1 | 2014 | 2 | 0.100 |
Why?
|
| Hospitals, Public | 1 | 2014 | 45 | 0.100 |
Why?
|
| Wrist Joint | 1 | 2013 | 3 | 0.100 |
Why?
|
| Ankle Joint | 1 | 2013 | 4 | 0.100 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2013 | 5 | 0.100 |
Why?
|
| Genetics, Population | 1 | 2013 | 52 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 2 | 0.100 |
Why?
|
| Middle East | 1 | 2012 | 8 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2003 | 17 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 39 | 0.090 |
Why?
|
| France | 2 | 2017 | 5 | 0.090 |
Why?
|
| Disabled Persons | 1 | 2012 | 23 | 0.090 |
Why?
|
| Fibrosis | 1 | 2012 | 11 | 0.090 |
Why?
|
| Collagen | 1 | 2012 | 23 | 0.090 |
Why?
|
| Uncompensated Care | 1 | 2011 | 2 | 0.090 |
Why?
|
| Biopsy | 1 | 2012 | 38 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2011 | 1 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2011 | 15 | 0.090 |
Why?
|
| Animals | 3 | 2012 | 1081 | 0.090 |
Why?
|
| Streptomycin | 1 | 2011 | 1 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2011 | 13 | 0.080 |
Why?
|
| Seizures | 1 | 2011 | 20 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 253 | 0.080 |
Why?
|
| Isoxazoles | 2 | 2001 | 4 | 0.080 |
Why?
|
| Range of Motion, Articular | 3 | 2018 | 6 | 0.080 |
Why?
|
| Scleroderma, Localized | 1 | 2010 | 1 | 0.080 |
Why?
|
| Joint Diseases | 1 | 2010 | 3 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 112 | 0.080 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2020 | 4 | 0.080 |
Why?
|
| Inflammation | 1 | 2010 | 104 | 0.080 |
Why?
|
| Cause of Death | 3 | 2017 | 221 | 0.080 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2006 | 5 | 0.080 |
Why?
|
| Tropical Climate | 1 | 2009 | 4 | 0.070 |
Why?
|
| Travel | 1 | 2009 | 21 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 20 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 5 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 111 | 0.070 |
Why?
|
| Employment | 1 | 2008 | 27 | 0.070 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2008 | 5 | 0.070 |
Why?
|
| Amebiasis | 1 | 1988 | 1 | 0.070 |
Why?
|
| Insect Vectors | 1 | 2009 | 99 | 0.070 |
Why?
|
| Brain Abscess | 1 | 1988 | 3 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 1999 | 36 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2008 | 203 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 1987 | 15 | 0.070 |
Why?
|
| Knee Joint | 2 | 2018 | 3 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2019 | 321 | 0.060 |
Why?
|
| Hemoglobins | 1 | 1987 | 40 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 127 | 0.060 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2006 | 1 | 0.060 |
Why?
|
| Sjogren's Syndrome | 1 | 2006 | 2 | 0.060 |
Why?
|
| HLA-DQ Antigens | 2 | 2004 | 8 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 163 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 106 | 0.060 |
Why?
|
| Malondialdehyde | 1 | 2005 | 3 | 0.060 |
Why?
|
| Self Report | 2 | 2016 | 114 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2005 | 19 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2005 | 4 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2005 | 14 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2005 | 1 | 0.060 |
Why?
|
| Islam | 1 | 2005 | 5 | 0.060 |
Why?
|
| Pregnancy, High-Risk | 1 | 2004 | 5 | 0.050 |
Why?
|
| Racism | 1 | 2024 | 4 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 472 | 0.050 |
Why?
|
| Africa, Southern | 1 | 2004 | 91 | 0.050 |
Why?
|
| United States | 1 | 2024 | 132 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2003 | 4 | 0.050 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2023 | 2 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2003 | 1 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2003 | 9 | 0.050 |
Why?
|
| Lim Kinases | 1 | 2022 | 4 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 14 | 0.050 |
Why?
|
| Knee | 2 | 2018 | 4 | 0.050 |
Why?
|
| Survival Rate | 1 | 2003 | 96 | 0.050 |
Why?
|
| Joints | 2 | 2014 | 9 | 0.050 |
Why?
|
| Lasers | 1 | 2021 | 2 | 0.040 |
Why?
|
| Perfusion | 1 | 2021 | 6 | 0.040 |
Why?
|
| Awareness | 1 | 2021 | 18 | 0.040 |
Why?
|
| Environment | 1 | 2021 | 22 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2021 | 1 | 0.040 |
Why?
|
| Electronic Mail | 1 | 2021 | 2 | 0.040 |
Why?
|
| Telephone | 1 | 2021 | 5 | 0.040 |
Why?
|
| Physical Examination | 1 | 2021 | 10 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2021 | 12 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 16 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2021 | 26 | 0.040 |
Why?
|
| Telemedicine | 1 | 2021 | 25 | 0.040 |
Why?
|
| Hand | 2 | 2003 | 5 | 0.040 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2019 | 3 | 0.040 |
Why?
|
| Health Policy | 1 | 2021 | 140 | 0.040 |
Why?
|
| Spouses | 1 | 2019 | 6 | 0.040 |
Why?
|
| Tobacco | 1 | 2019 | 14 | 0.040 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1999 | 1 | 0.040 |
Why?
|
| Fertility | 1 | 2019 | 22 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2019 | 15 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 1999 | 31 | 0.040 |
Why?
|
| Obesity | 2 | 2003 | 367 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 1 | 0.040 |
Why?
|
| Contraception | 1 | 2019 | 90 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 8 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 19 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2019 | 87 | 0.040 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2019 | 103 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 1999 | 45 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 56 | 0.040 |
Why?
|
| Premature Birth | 1 | 2019 | 80 | 0.040 |
Why?
|
| Computational Biology | 1 | 2018 | 44 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 10 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2018 | 89 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 107 | 0.030 |
Why?
|
| Occupations | 1 | 1998 | 13 | 0.030 |
Why?
|
| Postmenopause | 1 | 1998 | 11 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1998 | 23 | 0.030 |
Why?
|
| Protective Factors | 1 | 2017 | 7 | 0.030 |
Why?
|
| Gene Frequency | 4 | 2003 | 122 | 0.030 |
Why?
|
| Depression | 1 | 2019 | 121 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 1998 | 55 | 0.030 |
Why?
|
| Death Certificates | 1 | 2017 | 10 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 133 | 0.030 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1997 | 5 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 411 | 0.030 |
Why?
|
| Pulmonary Valve | 1 | 1997 | 1 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 1997 | 6 | 0.030 |
Why?
|
| Chorea | 1 | 1997 | 13 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 418 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 15 | 0.030 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 7 | 0.030 |
Why?
|
| Tobacco, Smokeless | 1 | 2016 | 7 | 0.030 |
Why?
|
| Psychotic Disorders | 1 | 1996 | 7 | 0.030 |
Why?
|
| Counterimmunoelectrophoresis | 1 | 1996 | 1 | 0.030 |
Why?
|
| Penicillamine | 1 | 1996 | 2 | 0.030 |
Why?
|
| Nifedipine | 1 | 1996 | 5 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1995 | 11 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 21 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 17 | 0.030 |
Why?
|
| DNA | 2 | 2011 | 73 | 0.030 |
Why?
|
| Foot | 1 | 1994 | 5 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1994 | 12 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 31 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 38 | 0.020 |
Why?
|
| Brain | 2 | 1997 | 53 | 0.020 |
Why?
|
| Matrilin Proteins | 1 | 2013 | 2 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 12 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Chemokines | 1 | 2011 | 9 | 0.020 |
Why?
|
| Synovitis | 1 | 2010 | 1 | 0.020 |
Why?
|
| Tendons | 1 | 2010 | 1 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 6 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 25 | 0.020 |
Why?
|
| Cardiolipins | 1 | 1990 | 1 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2001 | 272 | 0.020 |
Why?
|
| Histocompatibility Testing | 2 | 2003 | 26 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 1989 | 1 | 0.020 |
Why?
|
| Sepsis | 1 | 2010 | 102 | 0.020 |
Why?
|
| Pneumonia | 1 | 2010 | 131 | 0.020 |
Why?
|
| Neoplasms | 1 | 2010 | 147 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2008 | 3 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 9 | 0.020 |
Why?
|
| Base Sequence | 2 | 1999 | 149 | 0.020 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 1 | 0.020 |
Why?
|
| Hematocrit | 1 | 1987 | 6 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 1987 | 4 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1987 | 24 | 0.020 |
Why?
|
| Reference Values | 1 | 1987 | 64 | 0.020 |
Why?
|
| Altitude | 1 | 1987 | 9 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 149 | 0.020 |
Why?
|
| Marfan Syndrome | 1 | 2006 | 2 | 0.020 |
Why?
|
| Angiography | 1 | 2006 | 6 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2006 | 21 | 0.020 |
Why?
|
| Kidney | 1 | 2006 | 46 | 0.020 |
Why?
|
| Prothrombin | 1 | 2006 | 8 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2006 | 24 | 0.010 |
Why?
|
| Christianity | 1 | 2005 | 1 | 0.010 |
Why?
|
| Terrorism | 1 | 2005 | 1 | 0.010 |
Why?
|
| Prejudice | 1 | 2005 | 8 | 0.010 |
Why?
|
| Internationality | 1 | 2005 | 36 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 48 | 0.010 |
Why?
|
| United Kingdom | 1 | 2003 | 33 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 45 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 55 | 0.010 |
Why?
|
| Pan troglodytes | 1 | 1999 | 7 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 1999 | 60 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1999 | 175 | 0.010 |
Why?
|
| Collectins | 1 | 1998 | 1 | 0.010 |
Why?
|
| HLA-DR2 Antigen | 1 | 1995 | 1 | 0.010 |
Why?
|
| HLA-DQ beta-Chains | 1 | 1995 | 2 | 0.010 |
Why?
|
| Calcaneus | 1 | 1994 | 14 | 0.010 |
Why?
|
| Hemagglutination Tests | 1 | 1990 | 2 | 0.000 |
Why?
|
| Latex Fixation Tests | 1 | 1990 | 8 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1990 | 17 | 0.000 |
Why?
|